35 reports

  • Mar 28, 2016: Aerie Pharmaceuticals Initiates Second Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
  • Sep 14, 2016: Aerie Pharmaceuticals Reports Positive Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results
  • Ophthalmic Solution
  • Ophthalmology
  • Pharmaceutical
  • United States
  • Aerie Pharmaceuticals, Inc.
  • OCT 03, 2013: LUPIN LAUNCHES GENERIC ZYMAXID OPHTHALMIC SOLUTION IN THE US
  • JUL 01, 2013: LUPIN GETS FDA TENTATIVE APPROVAL FOR GATIFLOXACIN EYE DROPS
  • Eye Disease
  • Ophthalmic Solution
  • United States
  • Litigation And Patent
  • InSite Vision Incorporated
  • OCT 03, 2013: LUPIN LAUNCHES GENERIC ZYMAXID OPHTHALMIC SOLUTION IN THE US
  • JUL 01, 2013: LUPIN GETS FDA TENTATIVE APPROVAL FOR GATIFLOXACIN EYE DROPS
  • Eye Disease
  • Ophthalmic Solution
  • United States
  • Litigation And Patent
  • InSite Vision Incorporated
  • 11.3 NOVARTIS AG
  • Joint Venture
  • Ophthalmic Solution
  • World
  • Forecast
  • Market Size
  • Galderma S.A.
  • Clinical Trial profile. 41 Trial Title
  • Clinical Trial profile. 60 Trial Title
  • Ophthalmic Solution
  • Respiratory Treatment
  • World
  • Product Initiative
  • Alcon, Inc.
  • Clinical Trial profile. 465
  • Clinical Trial profile. 102
  • Allergy Drug
  • Clinical Trial
  • Ophthalmic Solution
  • World
  • Alcon, Inc.
  • Strengths
  • Scope of the report
  • Anti-Infective
  • Ophthalmic Solution
  • Akorn, Inc.
  • Alcon, Inc.
  • Allergan plc
  • 6.2.3 MUCOSTA OPHTHALMIC SOLUTION (REBAMIPIDE)
  • PRODUCT PROFILE - LIFITEGRAST
  • Ophthalmic Solution
  • Allergan plc
  • Herantis Pharma Plc
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Clinical Trial profile. 27 Trial Title
  • Clinical Trial profile. 175 Trial Title
  • Allergy Drug
  • Ophthalmic Solution
  • Therapy
  • World
  • Alcon, Inc.

Ophthalmic Solution Versus Vigamox in the Conjunctiva of Healthy Volunteers Following a Single Ocular Administration Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers GDCT## NCT##, ##-##; P## Ophthalmology Bacterial Conjunctiviti

  • Eye Disease
  • Healthcare
  • Ophthalmic Solution
  • World
  • Product Initiative
  • XENCOR INC
  • Allergic Conjunctivitis - Drug Profiles

The drug candidate is a topical ophthalmic solution containing high concentrations of hypochlorous acid as the active ingredient.

  • Ophthalmic Solution
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Weakness - Safety Concerns

In April, the company received the US FDA approval for its New Drug Application (NDA) for Prolensa (bromfenac ophthalmic solution) ##. ##% nonsteroidal anti-inflammatory ophthalmic solution.

  • Eye Disease
  • Ophthalmic Solution
  • Ophthalmology
  • United States
  • Bausch & Lomb Incorporated
  • 5.2.3 Mucosta ophthalmic solution (rebamipide)
  • Product Profile - Lifitegrast
  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • 5.2.3 Mucosta ophthalmic solution (rebamipide)
  • Product Profile - Lifitegrast
  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • 5.2.3 Mucosta ophthalmic solution (rebamipide)
  • Product Profile - Tavilermide
  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • JUL 22, 2016: VALEANT PHARMACEUTICALS RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA
  • BAUSCH & LOMB ENTERS INTO DISTRIBUTION AGREEMENT WITH MICRO LABS
  • Eye Disease
  • Ophthalmic Solution
  • Ophthalmology
  • United States
  • Bausch & Lomb Incorporated
  • 5.2.3 Mucosta ophthalmic solution (rebamipide)
  • Product Profile - Mucosta
  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • 5.2.3 Mucosta ophthalmic solution (rebamipide)
  • Product Profile - Lifitegrast
  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • APR 27, 2017: NICOX FIRST QUARTER 2017 BUSINESS UPDATE AND CASH POSITION
  • APR 15, 2016: NICOX: 2015 FINANCIAL RESULTS AND BUSINESS UPDATE

The drug candidate is administered as ophthalmic prep solution.

  • Eye Disease
  • Ophthalmic Solution
  • United States
  • M&A
  • NicOx S.A.
  • KEY M&A
  • Vendor landscape
  • Ophthalmic Solution
  • Akorn, Inc.
  • Alcon, Inc.
  • Allergan plc
  • Bausch & Lomb Incorporated

It offers near vision solutions and develops ophthalmic medical devices.

  • Eye Disease
  • Ophthalmic Solution
  • Ophthalmology
  • United States
  • Bausch & Lomb Incorporated
  • CETIRIZINE HYDROCHLORIDE - DRUG PROFILE
  • Regulatory Details

The drug candidate is a topical ophthalmic solution.

  • Ophthalmic Solution
  • OTC
  • Therapy
  • United States
  • Product Initiative
  • Implementing inorganic growth strategies Advancing its pipeline through increased investment in R&D
  • Vendor landscape

It is a polyvinyl alcohol ophthalmic solution, which consists of ##. ##% ocular lubricant sterile solution.

  • Ophthalmic Solution
  • Akorn, Inc.
  • Alcon, Inc.
  • Allergan plc
  • Bausch & Lomb Incorporated

The company has started providing ophthalmic solutions like Zeiss Ophthalmic Data Management Solution, Zeiss Toric Solution & Zeiss Refractive Laser Solution.

  • Ophthalmic Solution
  • Abbott Medical Optics, Inc.
  • Alcon, Inc.
  • Carl Zeiss Meditec AG
  • Essilor group

Multipurpose solutions and one step peroxide solutions are covered under this segment.

  • Ophthalmic Solution
  • Pharmaceutical
  • North America
  • Forecast
  • Valeant Pharmaceuticals International, Inc.

Ophthalmic Solution in Providing Symptomatic Relief in Subjects with Allergic Conjunctivitis A Clinical Trial to Assess the Efficacy and Safety of LP##-## Versus Olopatadine Ophthalmic Solution in Subjects with Allergic Conjunctivitis GDCT## CTRI/ 2011&#

  • Allergy Drug
  • Ophthalmic Solution
  • World
  • Product Initiative
  • Circassia Pharmaceuticals plc

For instance, the recent approval of Zerviate (cetirizine) for the treatment of allergic conjunctivitis in 2017 and Humira (adalimumab) and Xiidra (lifitegrast) in 2016 as ophthalmic solutions for the treatment of uveitis and dry eyes are expected to boost the market growth.

  • Ophthalmic Solution
  • OTC
  • Pharmaceutical
  • Forecast

Ophthalmic Solution ISOPTO Carpine Ophthalmic Solution ISOPTO Homatropine Ophthalmic Solution MAXIDEX Ophthalmic Suspension Ophthalmic Product/ Solution Contact Lenses Category S ALOMIDE Ophthalmic

  • Ophthalmic Solution
  • Market Size
  • Johnson & Johnson
  • Luxottica Group
  • Novartis AG

The company offers near vision solutions and develops ophthalmic medical devices.

  • Eye Disease
  • Ophthalmic Solution
  • North America
  • United States
  • Alcon, Inc.
  • TRENDS

ophthalmic solution in concentrations of ##. ##mg/ ml, ##. ##mg/ ml (##. ##%), ##mg/ ml and ##. ##mg/ ml, benefiting brands such as Luz Zul and Nazil Ofteno.

  • Ophthalmic Solution
  • OTC
  • Colombia
  • Demand